BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
Key Highlights
- ➤BioStem (BSEM) receives one U.S. patent for sterile human placental allografts
- ➤BioStem (BSEM) receives three U.S. patent application notices of allowance
- ➤Mexican patent application receives notice of allowance for placental allografts
- ➤Patent portfolio now includes more than 100 patents and applications worldwide
Expert Statements
Jason Matuszewski, Chair and CEO of BioStem Technologies
“Investing in our intellectual property remains a priority for BioStem, and this patent and four allowances reflect the progress of that effort,”
Jason Matuszewski, Chair and CEO of BioStem Technologies
“We plan to continue to commit resources to expanding and defending our patent estate, both in the U.S. and internationally, so that the technologies we develop stay protected as we grow our product offerings for clinicians and their patients.”
POMPANO BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that the United States Patent and Trademark Office (USPTO) has issued one patent and three notices of allowance for additional patent applications and the Mexican Institute of Industrial Property (IMPI) has issued one notice of allowance for additional patent applications.
The newly issued patent and allowed applications broaden BioStem's intellectual property portfolio across its placental and umbilical cord tissue technologies in wound care, surgical and joint applications.
Get started
Create a free account to read the full story.